Adam Maeder

Stock Analyst at Piper Sandler

(1.54)
# 1413
Out of 5,328 analysts
136
Total ratings
51.72%
Success rate
8.60%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
RMD ResMed
Maintains: Neutral
260 248
236.53 4.85% 3 Apr 24, 2025
EW Edwards Lifesciences
Upgrades: Overweight
73 80
75.51 5.95% 14 Apr 24, 2025
ISRG Intuitive Surgical
Maintains: Overweight
670 575
515.83 11.47% 19 Apr 23, 2025
ABT Abbott Laboratories
Reiterates: Overweight
133 145
130.7 10.94% 3 Apr 17, 2025
RXST RxSight
Initiates Coverage On: Neutral
18
14.71 22.37% 1 Apr 15, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
11 9
8.24 3.16% 7 Mar 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
260 233
158.18 47.3% 14 Feb 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
6 6
n/a n/a 16 Feb 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
52 80
n/a n/a 7 Jan 7, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
5 5
2.59 73.75% 3 Sep 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Hold
20 21
11.44 83.57% 2 May 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
18 20
n/a n/a 6 May 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
290 360
n/a n/a 10 Apr 2, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Overweight
7 8
4.37 83.07% 1 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
15 20
6.09 228.41% 8 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
75 71
n/a n/a 8 Jan 12, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
25 30
14.14 112.16% 2 May 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
6 5
2 150% 2 Mar 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
10 18
1.68 971.43% 2 Jan 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
104 99
37.06 167.13% 3 May 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 11
n/a n/a 5 Jun 14, 2021